Day: April 8, 2020

Correction: corrected technical mistake in Annex No 3 indicating the correct amount of authorized capital.Correction: the record day, which entitles shareholders of the Company by excercising rights of priority to acquire newly issued shares of the Company shall be 27 April 2020

Patikslinimas: ištaisyta techninė klaida priede Nr. 3 nurodant teisingą įstatinio kapitalo dydį.Patikslinimas: teisių apskaitos diena, suteikianti teisę Bendrovės akcininkams pasinaudojant pirmumo teise įsigyti Bendrovės naujai išleidžiamų akcijų – 2020 m. balandžio 27 d. Pranešame, kad AB „Klaipėdos nafta“, juridinio asmens kodas 110648893, buveinė registruota adresu Burių g. 19, Klaipėda (toliau – Bendrovė), valdybos iniciatyva ir sprendimu 2020 m. balandžio 10 d. 13:00 val. sušaukiamas Bendrovės neeilinis visuotinis akcininkų susirinkimas. Susirinkimas vyks Bendrovės buveinėje, adresu: Burių 19, Klaipėda, Bendrovės administracijos patalpose (II aukšto posėdžių salėje).Susirinkimo darbotvarkė:Dėl įstatinio kapitalo didinimo papildomu įnašu;Dėl AB „Klaipėdos nafta“ įstatų keitimo;Dėl AB „Klaipėdos nafta“ įstatinio kapitalo mažinimo;Dėl...

RESEARCH TRIANGLE PARK, N.C., April 08, 2020 (GLOBE NEWSWIRE) — Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the Company’s New Drug Application (NDA) seeking marketing approval for LIQ861 for the treatment of pulmonary arterial hypertension (PAH). Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a goal date of November 24, 2020. LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed using the Company’s novel PRINT technology and engineered with the goal of enhancing deep-lung delivery of treprostinil in PAH patients by means of a convenient,...

AUSTIN, Texas, April 08, 2020 (GLOBE NEWSWIRE) — Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with high unmet medical need, today announced the approval of its Clinical Trial Application (CTA) by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) for ACN00177, a novel engineered human enzyme therapy designed to treat Homocystinuria, a serious metabolic disorder characterized by elevated plasma homocysteine levels, leading to a wide range of life-altering complications and reduced life expectancy.“The approval of the CTA for ACN00177 is an important step forward for our Homocystinuria program and for patients who are in need of new treatment options. Given these unprecedented times, our...

BUENA, N.J., April 08, 2020 (GLOBE NEWSWIRE) — Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2019.Fourth Quarter 2019 HighlightsNet Revenues for the quarter decreased by 5% to $16.0 million compared to the same quarter in 2018, driven primarily by a decline in both U.S. contract manufacturing and international injectable revenues partially offset by a 24% increase in U.S. Teligent label topical revenues $3.0 million of product development and research expenses in the fourth quarter of 2019, a 16% decline compared to $3.6 million for the same quarter in 2018 Selling, general and administrative expenses decreased by 9% to $5.1 million in the fourth quarter of 2019, excluding a $1.9 million non-cash...

TORONTO, April 08, 2020 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) announced today the first deployment of its COVID-19 electronic screening tool to Region of Waterloo-owned Sunnyside Home Long-Term Care, in support of their response to the deepening COVID-19 crisis.The development of this screening tool followed Sunnyside Home’s request for a solution to manage and conduct ongoing resident screening for symptoms typical of COVID-19.VitalHub has leveraged its “DOCit” mobile app, which was specifically designed with these kind of screening initiatives in mind, to enable the rapid development of its COVID-19 screening solution. DOCit allows care facilities to easily configure and deploy any kind of screening or recurring task, enabling extremely high visibility compliance and reporting standards for...

LabCorp, UC San Diego and the National Institute of Allergy and Infectious Diseases are among the organizations utilizing PacBio’s highly accurate long-read sequencing technology to study SARS-CoV-2 and the related immune response to COVID-19MENLO PARK, Calif., April 08, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that it is working with commercial, academic and government research teams that are investigating SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic. The highly accurate long reads produced by the company’s Single Molecule, Real-Time (SMRT®) Sequencing technology can be used to resolve variants of the virus that exist within one individual or across a population of patients,...

GOFORE PLC COMPANY ANNOUNCEMENT 8 APRIL 2020 AT 14.30  Notice to the Annual General Meeting of Gofore Plc A. Matters on the agenda of the General Meeting  The following matters will be discussed at the General Meeting:  1. Opening of the meeting  2. Calling the meeting to order  3. Election of persons to scrutinise the minutes and to supervise the counting of votes  4. Recording the legality of the meeting  5. Recording the attendance at the meeting and adoption of the list of votes  CEO’s Review  6. Presentation of the Financial Statements, the Report of the Board of Directors and the Auditor’s Report for 2019  7. Adoption of the Financial Statements  8. Resolution on the use of the profit shown on the Balance Sheet and the payment of dividend  The company’s Board of Directors proposes that a dividend of EUR 0.20 per share will be...

GOFORE OYJ YHTIÖTIEDOTE 8.4.2020 KLO 14.30Gofore Oyj:n yhtiökokouskutsuGofore Oyj:n osakkeenomistajat kutsutaan varsinaiseen yhtiökokoukseen, joka pidetään keskiviikkona 29.4.2020 klo 16.00 yhtiön pääkonttorissa osoitteessa Kalevantie 2, 33100 Tampere. Kokoukseen ilmoittautuneiden vastaanottaminen ja äänestyslippujen jakaminen aloitetaan klo 15.15. Gofore suhtautuu koronavirusepidemiaan erittäin vakavasti, minkä vuoksi yhtiö kehottaa osakkeenomistajia olemaan saapumatta paikalle ja sen sijaan seuraamaan yhtiökokousta kaikille avoimen verkkolähetyksen välityksellä. Seuraamalla kokousta videoyhteyden kautta osakkeenomistaja ei osallistu kokoukseen eikä voi käyttää osakeyhtiölain mukaista kyselyoikeuttaan tai osallistua äänestyksiin. Linkki verkkolähetykseen on saatavilla yhtiön internet-sivuilta http://gofore.com/yhtiokokous2020. Mikäli osakkeenomistajia...

Investors House Oyj                                                                          Pörssitiedote 8.4.2020 klo 14.30TÄYDENNYS HALLITUKSEN EHDOTUKSIIN INVESTORS HOUSEN VARSINAISELLE YHTIÖKOKOUKSELLEInvestors House Oyj:n hallitus kutsui 7.4.2020 yhtiön osakkeenomistajat 28.4.2020 pidettävään varsinaiseen yhtiökokoukseen. Hallitus täydentää ehdotuksiaan yhtiökokoukselle koskien hallituksen jäsenten lukumäärää ja jäsenten valintaa.Täydennetyt ehdotukset:13. Hallituksen jäsenten lukumäärästä päättäminenHallitus ehdottaa, että hallitukseen valitaan viisi (5) jäsentä.14. Hallituksen jäsenten valintaHallitus ehdottaa, että hallitukseen valitaan Taina Ahvenjärvi, Mikko Larvala, Tapani Rautiainen, Joonas Rautiainen ja Petri Roininen. Ahvenjärvi, Larvala, Tapani Rautiainen ja Joonas Rautiainen ovat yhtiöstä riippumattomia. Ahvenjärvi, Larvala...